Remdesivir
IV antiviral for COVID-19.
- Starts working
- Varies
- Half-life
- About 1 hour (parent); metabolites longer
- In use since
- 2020
- Pregnancy
- Use with caution
Overview
Remdesivir was the first antiviral approved for COVID-19. It's given by drip in hospital, or as a 3-day course for high-risk outpatients, and shortens recovery in some groups.
Conditions it's used for
How it works
Slips into the virus's genetic material as it's copied and stops the process.
Remdesivir belongs to the RNA polymerase inhibitors. How RNA polymerase inhibitors work: slip into the virus's RNA as it is copied and halt the copying machinery.
Uses
- COVID-19 in hospital
- Early COVID-19 in high-risk outpatients (3 days)
Available as: iv infusion.
Typical dose
- Adults
- 200 mg on day 1, then 100 mg daily.
Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.
Side effects
Common
Often mild and may settle with time
- Nausea
- Raised liver enzymes
Serious — get medical help
Uncommon, but need prompt attention
- Infusion reactions
- Slow heart rate
- Liver injury
Warnings
- Liver tests during treatment
Interactions
- Chloroquine and hydroxychloroquine — reduce its effect
Pregnancy and breastfeeding
Use with caution
Used when benefits outweigh risks.
Breastfeeding advice can differ from pregnancy advice — check with a pharmacist, or the LactMed database.
Brand names
- United States
- Veklury
- United Kingdom
- Veklury
- India
- Covifor, Cipremi
Examples only; many generic versions exist. The same brand name can mean different products in different countries.
History
It was originally developed for hepatitis C and then tested against Ebola.
Common questions
Is it a cure?
No, it modestly speeds recovery; vaccines and early treatment matter most.
Do I need a prescription for Remdesivir?
Yes — Remdesivir is prescription-only in most countries.
Can I take Remdesivir during pregnancy?
Use with caution. Used when benefits outweigh risks. Always check with a doctor or midwife.
Related medicines
Sources and official information
- MedlinePlus (US National Library of Medicine)
- DailyMed — official US labels
- NHS medicines A–Z
- WHO ATC/DDD index — J05AB16
Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.